In vitro and in vivo metabolism of a novel FTpase inhibitor LB42908 and its effects on the CYP isozyme activities

被引：0
|
作者：
Lee, Sung Hack [1 ]
Kim, Ho Jun [1 ]
Koh, Jong Sung [1 ]
机构：
[1] LG Life Sci, Res Dev Pk, Taejon, South Korea
来源：
DRUG METABOLISM REVIEWS | 2006年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities
    Chang, Minsun
    Lee, Sung-Hak
    Kim, Ho Jun
    Koh, Jong-Sung
    Kim, Aeri
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (09) : 3067 - 3071
  • [2] Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities (vol 22, pg 3067, 2012)
    Kim, Ho Jun
    Lee, Sung Hak
    Koh, Jong-Sung
    Lee, Sun Hwa
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (07) : 1862 - 1862
  • [3] RETRACTION: Corrigendum to " Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities (vol 24, 1862, 2014)
    Chang, Minsun
    Lee, Sung-Hak
    Kim, Ho Jun
    Koh, Jong-Sung
    Kim, Aeri
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 109
  • [4] RETRACTION: Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities (Retraction of Vol 22, Pg 3067, 2012)
    Chang, Minsun
    Lee, Sung-Hak
    Kim, Ho Jun
    Koh, Jong-Sung
    Kim, Aeri
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 104
  • [5] Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo
    Xie, Hua
    Lee, Mee-Hyun
    Zhu, Feng
    Reddy, Kanamata
    Huang, Zunnan
    Kim, Dong Joon
    Li, Yan
    Peng, Cong
    Lim, Do Young
    Kang, Soouk
    Jung, Sung Keun
    Li, Xiang
    Li, Haitao
    Ma, Weiya
    Lubet, Ronald A.
    Ding, Jian
    Bode, Ann M.
    Dong, Zigang
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 950 - 958
  • [6] In Vitro and In Vivo Metabolism and Inhibitory Activities of Vasicine, a Potent Acetylcholinesterase and Butyrylcholinesterase Inhibitor
    Liu, Wei
    Shi, Xiaoyuan
    Yang, Yadi
    Cheng, Xuemei
    Liu, Qing
    Han, Han
    Yang, Baohua
    He, Chunyong
    Wang, Yongli
    Jiang, Bo
    Wang, Zhengtao
    Wang, Changhong
    [J]. PLOS ONE, 2015, 10 (04):
  • [7] In vitro and in vivo activities of Syn2190, a novel β-lactamase inhibitor
    Nishida, K
    Kunugita, C
    Uji, T
    Higashitani, F
    Hyodo, A
    Unemi, N
    Maiti, SN
    Phillips, OA
    Spevak, P
    Atchison, KP
    Salama, SM
    Atwal, H
    Micetich, RG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) : 1895 - 1900
  • [8] Discovery of a novel FAK inhibitor, NVP-TAE226, and its activities on in vivo and in vitro models
    Kawahara, E.
    Yamaura, T.
    Ohmori, O.
    Nonomura, K.
    Murakami, Y.
    Niwa, S.
    Meyer, T.
    Mestan, J.
    Honda, T.
    Hatakeyama, S.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 170 - 170
  • [9] In vitro and in vivo metabolism of a novel p38 kinase inhibitor
    Mitra, Kaushik
    Samuel, Koppara
    Natarajan, Swami-nathan
    Kumar, Sanjeev
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (12) : 2017 - 2017
  • [10] In vitro and in vivo metabolism of a novel p38 kinase inhibitor
    Mitra, Kaushik
    Samuel, Koppara
    Natarajan, Swaminathan
    Kumar, Sanjeev
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
12345